Stay updated on DSP-5336 in Relapsed AML Clinical Trial

Sign up to get notified when there's something new on the DSP-5336 in Relapsed AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the DSP-5336 in Relapsed AML Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page footer revision/version indicator was updated from **v3.5.2** to **v3.5.3**.
    Difference
    0.0%
    Check dated 2026-04-26T08:19:06.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-19T01:32:33.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    30 days ago
    Change Detected
    Summary
    - Added Horizon-1 Phase 1/2 study of Enzomenib (DSP-5336) in acute leukemia with multiple arms, SOC combinations, and a detailed global site list. Replaced the former DSP-5336 relapsed/refractory AML/ALL study description with the Horizon-1 protocol and expanded indications and design.
    Difference
    8%
    Check dated 2026-03-28T13:44:52.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    Revision indicator updated to v3.5.0. The previous revision v3.4.3 was removed.
    Difference
    0.0%
    Check dated 2026-03-21T08:39:32.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3; no visible content changes.
    Difference
    0.0%
    Check dated 2026-03-06T18:39:41.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2; Deleted Revision: v3.4.1.
    Difference
    0.0%
    Check dated 2026-02-13T12:33:23.000Z thumbnail image

Stay in the know with updates to DSP-5336 in Relapsed AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the DSP-5336 in Relapsed AML Clinical Trial page.